the research // logged to source
CJC-1295 Ipamorelin Research: Two Receptors, One Amplified Pulse
Mechanism, the GH and IGF-1 numbers, the human synergy evidence, and the comparisons — each finding pinned to its study.
Start here
CJC-1295 Ipamorelin research comes in two layers. The strong layer is single-component: what CJC-1295 does, what ipamorelin does, each measured on its own. The inferred layer is the combination: how the two behave together, which rests on general GHRH+GHRP synergy work done with related peptides, not this exact pair.
The short mechanism: growth hormone (GH) is released by cells in the pituitary gland called somatotrophs. They have two relevant switches. CJC-1295 hits the GHRH switch (raising cAMP, a cell messenger). Ipamorelin hits the ghrelin switch (raising calcium, a different messenger). Flip both at once and you get more GH out than flipping either alone — the "supra-additive" effect. Below: the studies, by claim. Doses appear only as what was given to which species by which route — never as human instructions.
Cjc-1295 ipamorelin
The pairing is a GHRH analogue plus a selective GHRP, chosen because the two arms fire through independent, complementary pathways. CJC-1295 binds the GHRH receptor — a class-B GPCR on somatotrophs — and signals via Gs → adenylyl cyclase → cAMP → PKA, driving GH gene transcription and secretion [5]. Ipamorelin binds GHS-R1a, the ghrelin receptor, and signals via Gq → phospholipase C → IP3 → intracellular calcium release, triggering GH granule release [2].
The ghrelin arm does more than stimulate directly. It also opposes somatostatin — the hypothalamic brake on GH — at both the pituitary and the GHRH neurons, and it can induce GHRH secretion [8]. A 2021 review integrates the circuit: ghrelin (and synthetic GHS-R1a agonists like ipamorelin) co-localizes with GHRH in hypothalamic neurons, facilitates GHRH release by inhibiting somatostatin, and acts synergistically with GHRH to stimulate GH synthesis [9]. Two amplifications, one output.
Ipamorelin cjc 1295
Take the components in the other order — ipamorelin first. Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide and the first selective GH secretagogue. In rat pituitary cells and conscious swine it released GH as effectively as GHRP-6, but — and this is the headline — it did not raise ACTH or cortisol above GHRH-stimulated levels even at doses over 200× the dose needed for GH release [2]. Older GHRPs spill over onto the stress (HPA) axis; ipamorelin stays in its lane.
CJC-1295 supplies the long, steady GHRH background the short ipamorelin pulse rides on. A single subcutaneous dose in healthy adults raised mean plasma GH 2- to 10-fold for six or more days and IGF-1 1.5- to 3-fold for 9–11 days; after multiple doses IGF-1 stayed above baseline up to 28 days [1]. That durability is what distinguishes the DAC form, covered on its own page.
Cjc 1295 and ipamorelin
The combination thesis stands on direct synergy evidence. The foundational human result: in 18 normal adult men, submaximal GHRP doses (0.1 and 0.3 µg/kg) combined with GHRH (1 µg/kg) stimulated GH release synergistically, the two acting through independent mechanisms [3]. That is the mechanistic rationale for pairing a GHRH analogue with a GHRP, demonstrated in people — though with related peptides, not this exact CJC-1295/ipamorelin pair.
The receptor-level mechanism followed. Co-activating the cloned ghrelin and GHRH receptors in transfected HeLa cells produced a cAMP response roughly twice that of GHRH-receptor activation alone, suggesting direct receptor cross-talk [4]. A deterministic model of pulsatile GH secretion confirmed the in-vivo synergy and laid out the four routes the ghrelin arm uses: direct pituitary stimulation, somatostatin antagonism at both pituitary and GHRH neurons, and induction of GHRH secretion [8]. The synergy is real and reproducible at the pathway level. What is missing is a controlled trial of the fixed blend itself.
Growth hormone secretagogue
Both halves are growth hormone secretagogues — compounds that make the body release its own GH rather than supplying GH directly. That is the category, and it matters for reading the evidence and the risk. A secretagogue works through the intact pituitary and preserves the body's own feedback (IGF-1 still brakes the axis), which is the mechanistic argument for a gentler profile than exogenous GH.
The class safety synthesis: a review of GH secretagogues found them well tolerated overall, with the chief safety concern being increased blood glucose from decreased insulin sensitivity; long-term data on cancer incidence and mortality are still needed [6]. A 2026 gerontology review groups ipamorelin among non-approved peptides lacking long-term safety data and validated monitoring frameworks, contrasting them with FDA-approved agents that carry large-trial safety profiles. Useful class context — not a verdict on this blend.
Ipamorelin vs sermorelin
Ipamorelin vs sermorelin is a category confusion worth clearing up: they are not the same kind of peptide. Sermorelin is a GHRH analogue — same family as the CJC-1295 half of this stack, working the GHRH receptor. Ipamorelin is a GHRP, working the ghrelin receptor. They are not competitors; they are the two arms a synergy stack combines.
So "which is better" is the wrong frame. The mechanistic point is that a GHRH analogue (sermorelin- or CJC-1295-type) and a GHRP (ipamorelin) are complementary — combining the two arms produces the supra-additive GH release that single-arm use does not [3][4]. What separates CJC-1295 from sermorelin within the GHRH arm is durability: the DAC form's albumin binding extends GH and IGF-1 elevation to days [1][5], where unmodified GHRH fragments are cleared in minutes.
Ipamorelin vs tesamorelin
Ipamorelin vs tesamorelin is another GHRP-vs-GHRH-analogue contrast, not a like-for-like. Tesamorelin is a GHRH analogue with the most robust human outcome data in this neighborhood. A 2026 meta-analysis of 5 randomized controlled trials of tesamorelin found significant reductions in visceral adipose tissue (mean difference −27.71 cm²) and hepatic fat (−4.28%), increased lean body mass (+1.42 kg) and IGF-1, with no serious adverse events or glucose perturbation [7].
That is the freshest high-quality evidence that GHRH-analogue stimulation of the GH/IGF-1 axis drives visceral- and hepatic-fat reduction with a manageable profile — useful read-across context for the GHRH (CJC-1295) arm of this stack. The honest caveat: that data is for tesamorelin monotherapy at its studied doses, not for ipamorelin and not for the CJC-1295 + ipamorelin combination, which has no comparable human outcome trial.